INTRODUCTION: @entity1082 ) is the main cause of @entity5 . In France, since March 2007, HPV vaccination has been recommended for @entity1 aged 14, in addition to a catch-up program for @entity1 aged 15 to 23. In October 2012, the target population was changed to 11- to 14-year-old @entity1 . The main objective of the present study was to evaluate the impact of the recommendation change on HPV vaccination coverage and compliance. METHODS: We conducted a descriptive study of the   chantillon G  n  raliste des B  n  ficiaires (EGB), which is a random 1/97 permanent sample from the French National Health Insurance Database. We focused our analyses on @entity1 aged 11 to 17 years who were covered by the main insurance scheme (which covers 77% of the French population). RESULTS: We included 16,195 @entity1 in this analysis. At the last update of the database (06/15/2014), 42% of 17-year-old @entity1 had been vaccinated, with more than 50% of them having been vaccinated at age 14. Between January 2012 and June 2014, @entity1 were reimbursed for a total of 7698 doses of the HPV vaccine. During the first trimester of 2013, the number of vaccinated 11- to 13-year-old @entity1 increased, growing by more than 20-fold between the last trimester of 2012 (n=8) and the last trimester of 2013 (n=178). Less than 60% of the vaccinated @entity1 received 3 injections. DISCUSSION: Implementation of the new recommendations was rapid but had only a slight impact on vaccination coverage.

Age impact on XXXX vaccination in France in 2014: A study from the National Health Insurance Database.

@entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer'] @entity1 :: ('9606', 'Species') :: ['patients', 'girls'] @entity1082 :: ('10566', 'Species') :: ['Human papillomavirus (HPV']
@entity1082 :: (10566,Species) :: ['human papillomavirus']
